As people with MS age, how does their response to their long-term DMT change? Is there a time when disease-modifying therapy can be safely discontinued? In which patients? At what age? What role do comorbidities play in making these decisions?  

Join us as we discuss these questions with Dr. Burcu Zeydan from the Mayo Clinic in this eMultipleSclerosis Review podcast. 

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.